Please use this identifier to cite or link to this item:
Title: Lot-to-lot consistency of a tetravalent dengue vaccine in healthy adults in Australia: a randomised study.
Austin Authors: Torresi, Joseph ;Heron, Leon G;Qiao, Ming;Marjason, Joanne;Chambonneau, Laurent;Bouckenooghe, Alain;Boaz, Mark;van der Vliet, Diane;Wallace, Derek;Hutagalung, Yanee;Nissen, Michael D;Richmond, Peter C
Affiliation: Global Clinical Immunology, Sanofi Pasteur, Swiftwater, PA, USA
Department of Infectious Diseases, Austin Health, Heidelberg, Victoria, Australia
University of Western Australia School of Paediatrics and Child Health and Vaccine Trials Group, Telethon Kids Institute, Subiaco, WA, Australia
Clinical Trials Centre, Queensland Paediatric Infectious Diseases Laboratory, Queensland Children's Medical Research Institute, Royal Children's Hospital, Herston, QLD, Australia
Department of Microbiology and Immunology, University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Parkville, Melbourne, Victoria, Australia
National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, The Children's Hospital at Westmead, Westmead, NSW, Australia
Royal Adelaide Hospital, SA Pathology, Adelaide, SA, Australia
Q-Pharm Pty Ltd, Herston 4006, QLD, Australia
Clinical Development, Sanofi Pasteur, Marcy l'Etoile, France
Clinical Development, Sanofi Pasteur, Singapore, Singapore
Issue Date: 22-Sep-2015
Date: 2015-08-13
Publication information: Vaccine 2015; 33(39): 5127-5134
Abstract: The recombinant yellow fever-17D-dengue virus, live, attenuated, tetravalent dengue vaccine (CYD-TDV) has undergone extensive clinical trials. Here safety and consistency of immunogenicity of phase III manufacturing lots of CYD-TDV were evaluated and compared with a phase II lot and placebo in a dengue-naïve population. Healthy 18-60 year-olds were randomly assigned in a 3:3:3:3:1 ratio to receive three subcutaneous doses of either CYD-TDV from any one of three phase III lots or a phase II lot, or placebo, respectively in a 0, 6, 12 month dosing schedule. Neutralising antibody geometric mean titres (PRNT50 GMTs) for each of the four dengue serotypes were compared in sera collected 28 days after the third vaccination-equivalence among lots was demonstrated if the lower and upper limits of the two-sided 95% CIs of the GMT ratio were ≥0.5 and ≤2.0, respectively. 712 participants received vaccine or placebo and 614 (86%) completed the study; 17 (2.4%) participants withdrew after adverse events. Equivalence of phase III lots was demonstrated for 11 of 12 pairwise comparisons. One of three comparisons for serotype 2 was not statistically equivalent. GMTs for serotype 2 in phase III lots were close to each other (65.9, 44.1 and 58.1, respectively). Phase III lots can be produced in a consistent manner with predictable immune response and acceptable safety profile similar to previously characterised phase II lots. The phase III lots may be considered as not clinically different as statistical equivalence was shown for serotypes 1, 3 and 4 across the phase III lots. For serotype 2, although equivalence was not shown between two lots, the GMTs observed in the phase III lots were consistently higher than those for the phase II lot. As such, in our view, biological equivalence for all serotypes was demonstrated.
DOI: 10.1016/j.vaccine.2015.08.008
ORCID: 0000-0002-8212-0887
Journal: Vaccine
PubMed URL: 26279339
Type: Journal Article
Subjects: Dengue
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Apr 22, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.